We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck KGaA, Darmstadt, Germany announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation.....
Merck KGaA has announced new and updated results from expansion cohorts of two ongoing Phase I clinical trials (NCT02517398 and NCT02699515) for its immunotherapy M7824.